Founder of BayHisto and a translational cancer biologist with nearly two decades of post-PhD research experience at Massachusetts General Hospital and Harvard Medical School. His work spans tumor immunology, cell and gene therapy engineering, and — most directly relevant to BayHisto — hands-on histopathology: designing IHC panels, running spatial immune phenotyping studies, and characterizing tumor tissue architecture for his own federally funded research.
BayHisto grew out of a simple observation from that work: research groups across the Boston–Cambridge corridor consistently need flexible, high-quality histology support that hospital core facilities — built first for clinical caseloads — aren't set up to give them quickly.
BayHisto processes specimens exclusively for academic and biotechnology research. No clinical or diagnostic testing is performed on any sample, and no results are used for patient care or treatment decisions.
Core histology — processing, sectioning, special stains, and IHC — is fully operational today. Automated IHC staining and, longer term, spatial molecular profiling are on the roadmap as client volume grows.